Search results
Abbvie Inc (ABBV) Shares Up Despite Recent Market Volatility – News Heater
NewsHeater· 6 days agoThe stock price of Abbvie Inc (NYSE: ABBV) has surged by 1.06 when compared to previous closing price of 164.66, but the company has ...
AbbVie Lifts FY24 Outlook After Higher Q1 Results - Update
RTT News· 2 days agoAbbVie Inc. (ABBV), while announcing higher first-quarter earnings, on Friday raised its outlook for fiscal 2024. In pre-market activity on the NYSE, AbbVie shares were gaining around 1.
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
Zacks via Yahoo Finance· 2 days agoAbbVie Inc. ABBV reported adjusted earnings of $2.31 per share for first-quarter 2024, beating the...
AbbVie: Q1 Earnings Snapshot
Midland Reporter-Telegram· 2 days agoNORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday...
AbbVie Q1 Preview: Skyrizi and Rinvoq’s launches could help Q1 (NYSE:ABBV)
Seeking Alpha· 3 days agoAbbVie (ABBV) is set to report Q1 earnings results on April 26th. Analysts expect a profit of $2.26...
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 6 days agoEarnings Surprise History AbbVie’s performance has been impressive, with its earnings beating...
‘AI Craze’ Powers Best Week in 2024 for Stocks: Markets Wrap
Bloomberg via Yahoo Finance· 1 day ago(Bloomberg) -- A rally in the world’s largest technology companies lifted stocks, with Wall Street...
Cigna to offer Humira rivals with $0 copay at specialty pharmacy
Reuters· 2 days agoCigna plans to make close copies of AbbVie's blockbuster arthritis drug Humira available with no...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CHRD, AA, FUSN, LABP
WKBN 27 Youngstown· 5 days agoUnder the terms of the proposed transaction, each common share of Enerplus will be exchanged for 0.10125 shares of Chord common stock and $1.84 per share in cash. Upon completion ...
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks via Yahoo Finance· 4 days agoAbbVie’s top line is expected to have been driven by sales of new immunology drugs, Skyrizi and...
